Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-10-08

FDA Approved: RIFADIN IV — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

The FDA approved a supplemental application for Rifadin IV (rifampin) submitted by Sanofi-Aventis U.S. LLC. This action covers the intravenous rifampin formulat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RIFADIN IV (rifampin)

Snippet

SUPPL AP for RIFADIN IV (RIFAMPIN)